Hansoh Pharma stock gets HKD 47.82 consensus target
Published on 10/17/2026 at 21:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and valuation
- Simply Wall St cited a HKD 47.82 consensus target on October 15, 2026.
- Hansoh posted CNY 4.26 billion in first-half net income, up 36.00 percent year over year.
- Hansoh Pharma stock stood at HKD 31.74 on October 16, 2026 at 4:08 p.m. HKT, up 1.15 percent on the Hong Kong Stock Exchange versus the HKD 31.38 prior close of October 15, 2026.
- Hansoh traded at a P/E ratio of 24.77 and a market capitalization of HKD 192.4 billion as of October 16, 2026.
Simply Wall St cited a consensus target of HKD 47.82 for Hansoh Pharma on October 15, 2026, putting the target 50.66 percent above the HKD 31.74 last price on October 16, 2026 at 4:08 p.m. HKT. Hansoh Pharma stock had gained 1.15 percent on the Hong Kong Stock Exchange versus the HKD 31.38 prior close.
That target is the clearest valuation marker for investors tracking Hansoh Pharma stock after the recent pullback. The Hong Kong-listed company remains focused on oncology, metabolic diseases, immunology, central nervous system treatments and anti-infectives, according to Hansoh Pharma.
First-half earnings support the valuation
Simply Wall St reported first-half 2026 revenue of CNY 8.30 billion, up 12.00 percent from the first half of 2025. Net income reached CNY 4.26 billion, an increase of 36.00 percent, while earnings per share rose to CNY 0.70 from CNY 0.53.
The earnings profile gives the target a measurable operating backdrop. The same first-half report showed a 51.00 percent profit margin, compared with 42.00 percent a year earlier, while the stock's 24.77 P/E ratio remains above the broader Hong Kong pharmaceutical industry average cited in the analysis.
Stock remains above its yearly low
Hansoh's share price stood 28.22 percent below its HKD 44.22 52-week high and 13.12 percent above its HKD 28.06 52-week low as of October 16, 2026. Trading volume was 10,482,420 shares, compared with an average volume of 10,274,123 shares.
Valuation and payment date
The market capitalization was HKD 192.4 billion and the trailing P/E ratio was 24.77 on October 16, 2026. The trailing dividend yield was 0.02 percent. Simply Wall St lists October 29, 2026 as the payment date for the HKD 0.28 first-half dividend.
Comparison with peers
Hansoh Pharma: plus 1.15 percent, P/E 24.77, market capitalization HKD 192.4 billion.
Innovent Biologics (Hong Kong Stock Exchange, HKD): plus 1.48 percent, P/E 113.34, market capitalization HKD 155.3 billion.
Sino Biopharmaceutical (Hong Kong Stock Exchange, HKD): minus 0.38 percent, P/E 33.78, market capitalization HKD 93.5 billion.
Hong Kong trading context
Hansoh Pharma last stood at HKD 31.74 on the Hong Kong Stock Exchange on October 16, 2026 at 4:08 p.m. HKT, up 1.15 percent from the HKD 31.38 prior close.
Hansoh Pharma key facts
- Company: Hansoh Pharmaceutical Group Company Limited
- ISIN: KYG549581067
- Ticker: 03692.HK
- Primary exchange: Hong Kong Stock Exchange
- Price on the Hong Kong Stock Exchange as of October 16, 2026, 4:08 p.m. HKT: HKD 31.74
- Change on the day: plus 1.15 percent
- Market capitalization: HKD 192.4 billion as of October 16, 2026
- 52-week range: HKD 28.06-HKD 44.22 as of October 16, 2026
- Sector / Industry: Healthcare / Drug Manufacturers - Specialty and Generic
Market context: Current market reports.
